NASDAQ:IOVAIovance Biotherapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Iovance Biotherapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $27.83 -0.83 (-2.90 %) (As of 08/14/2020 10:49 AM ET) Add Compare Share Today's Range$27.75Now: $27.83▼$28.7650-Day Range$27.21MA: $29.14▼$31.6652-Week Range$17.67Now: $27.83▼$41.49Volume3,149 shsAverage Volume1.86 million shsMarket Capitalization$4.08 billionP/E RatioN/ADividend YieldN/ABeta1.1 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma. It is also developing LN-145, an autologous adoptive cell therapy to treat cervical and head and neck cancers. The company has research collaboration and clinical grant agreements with Moffitt to evaluate TIL therapy in a clinical trial that combines TIL with nivolumab in NSCLC; strategic alliance agreement with M.D. Anderson Cancer Center to conduct clinical and preclinical research studies; strategic alliance agreement with Roswell Park Cancer Institute to conduct a clinical research study of TIL therapy in bladder cancer; collaboration agreement with MedImmune to conduct clinical and preclinical research in immuno-oncology; preclinical research collaboration with the Ohio State University; and a preclinical research collaboration with Cellectis S.A. to investigate transcription activator-like effector nucleases. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was founded in 2007 and is headquartered in San Carlos, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingIovance Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 13 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $45.17, Iovance Biotherapeutics has a potential upside of 59.8% from its current price of $28.26.Amount of Analyst CoverageIovance Biotherapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 3.2 Community Rank Outperform VotesIovance Biotherapeutics has received 483 “outperform” votes. (Add your “outperform” vote.)Underperform VotesIovance Biotherapeutics has received 274 “underperform” votes. (Add your “underperform” vote.)Community SentimentIovance Biotherapeutics has received 63.80% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Iovance Biotherapeutics and other stocks. Vote “Outperform” if you believe IOVA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IOVA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldIovance Biotherapeutics does not currently pay a dividend.Dividend GrowthIovance Biotherapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Iovance Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.90% of the stock of Iovance Biotherapeutics is held by insiders.Percentage Held by Institutions95.52% of the stock of Iovance Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Iovance Biotherapeutics are expected to decrease in the coming year, from ($2.08) to ($2.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Iovance Biotherapeutics is -14.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Iovance Biotherapeutics is -14.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIovance Biotherapeutics has a P/B Ratio of 11.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.54 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IOVA Previous Symbol CUSIPN/A CIK1425205 Webwww.iovance.com Phone650-260-7120Debt Debt-to-Equity RatioN/A Current Ratio14.26 Quick Ratio14.25Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.37 per share Price / Book11.74Profitability EPS (Most Recent Fiscal Year)($1.59) Net Income$-197,560,000.00 Net MarginsN/A Return on Equity-59.35% Return on Assets-53.22%Miscellaneous Employees88 Outstanding Shares146,443,000Market Cap$4.08 billion Next Earnings Date11/2/2020 (Estimated) OptionableOptionable $27.83 -0.83 (-2.90 %) (As of 08/14/2020 10:49 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive IOVA News and Ratings via Email Sign-up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter. Iovance Biotherapeutics (NASDAQ:IOVA) Frequently Asked Questions How has Iovance Biotherapeutics' stock been impacted by COVID-19 (Coronavirus)? Iovance Biotherapeutics' stock was trading at $29.58 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, IOVA stock has decreased by 5.9% and is now trading at $27.83. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Iovance Biotherapeutics? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last year. There are currently 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Iovance Biotherapeutics. When is Iovance Biotherapeutics' next earnings date? Iovance Biotherapeutics is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020. View our earnings forecast for Iovance Biotherapeutics. How were Iovance Biotherapeutics' earnings last quarter? Iovance Biotherapeutics Inc (NASDAQ:IOVA) issued its quarterly earnings results on Thursday, August, 6th. The biotechnology company reported ($0.47) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.52) by $0.05. View Iovance Biotherapeutics' earnings history. What price target have analysts set for IOVA? 13 brokers have issued 12-month price objectives for Iovance Biotherapeutics' shares. Their forecasts range from $28.00 to $65.00. On average, they expect Iovance Biotherapeutics' stock price to reach $45.17 in the next year. This suggests a possible upside of 62.3% from the stock's current price. View analysts' price targets for Iovance Biotherapeutics. Has Iovance Biotherapeutics been receiving favorable news coverage? Media headlines about IOVA stock have trended positive this week, according to InfoTrie. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Iovance Biotherapeutics earned a news impact score of 2.7 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the near future. View the latest news about Iovance Biotherapeutics. Who are some of Iovance Biotherapeutics' key competitors? Some companies that are related to Iovance Biotherapeutics include BioNTech (BNTX), Qiagen (QGEN), argenx (ARGX), Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), Novavax (NVAX), Repligen (RGEN), Crispr Therapeutics (CRSP), Acceleron Pharma (XLRN), Allogene Therapeutics (ALLO), Adaptive Biotechnologies (ADPT), Spark Therapeutics (ONCE), bluebird bio (BLUE), China Biologic Products (CBPO) and Halozyme Therapeutics (HALO). View all competitors. What other stocks do shareholders of Iovance Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Applied Materials (AMAT), Portola Pharmaceuticals (PTLA), Immunomedics (IMMU), Kadmon (KDMN), Bristol-Myers Squibb (BMY), NVIDIA (NVDA), Seattle Genetics (SGEN), BlackRock (BLK), CA (CA) and Advanced Micro Devices (AMD). Who are Iovance Biotherapeutics' key executives? Iovance Biotherapeutics' management team includes the following people: Dr. Maria Fardis, CEO, Pres & Director (Age 51)Mr. Timothy E. Morris, CFO, Principal Accounting Officer, Corp. Sec. & Treasurer (Age 57)Dr. Frederick G. Vogt Ph.D., Esq., Gen. Counsel (Age 45)Mr. Howard B. Johnson, Sr. VP of Corp. Devel., Alliance Management & Program Management (Age 59)Dr. Elma S. Hawkins Ph.D., MBA, Advisor to the Board (Age 62) What is Iovance Biotherapeutics' stock symbol? Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA." Who are Iovance Biotherapeutics' major shareholders? Iovance Biotherapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.35%), FMR LLC (2.23%), Sumitomo Mitsui Trust Holdings Inc. (2.18%), Victory Capital Management Inc. (1.78%), Goldman Sachs Group Inc. (0.98%) and Bank of New York Mellon Corp (0.72%). Company insiders that own Iovance Biotherapeutics stock include Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum. View institutional ownership trends for Iovance Biotherapeutics. Which major investors are selling Iovance Biotherapeutics stock? IOVA stock was sold by a variety of institutional investors in the last quarter, including Mangrove Partners, Prosight Management LP, State of Wisconsin Investment Board, Strs Ohio, Nicholas Investment Partners LP, FMR LLC, American International Group Inc., and Mackay Shields LLC. View insider buying and selling activity for Iovance Biotherapeutics. Which major investors are buying Iovance Biotherapeutics stock? IOVA stock was bought by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Vanguard Group Inc., Candriam Luxembourg S.C.A., Goldman Sachs Group Inc., Jennison Associates LLC, Victory Capital Management Inc., Marshall Wace North America L.P., and New York State Common Retirement Fund. Company insiders that have bought Iovance Biotherapeutics stock in the last two years include Iain D Dukes, Merrill A Mcpeak, and Wayne P Rothbaum. View insider buying and selling activity for Iovance Biotherapeutics. How do I buy shares of Iovance Biotherapeutics? Shares of IOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Iovance Biotherapeutics' stock price today? One share of IOVA stock can currently be purchased for approximately $27.83. How big of a company is Iovance Biotherapeutics? Iovance Biotherapeutics has a market capitalization of $4.08 billion. The biotechnology company earns $-197,560,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis. Iovance Biotherapeutics employs 88 workers across the globe. What is Iovance Biotherapeutics' official website? The official website for Iovance Biotherapeutics is www.iovance.com. How can I contact Iovance Biotherapeutics? Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The biotechnology company can be reached via phone at 650-260-7120 or via email at [email protected] This page was last updated on 8/14/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
